Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $396.10 million. The enterprise value is $309.43 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, after market close.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 363.40 million shares outstanding. The number of shares has increased by 38.44% in one year.
| Current Share Class | 363.40M |
| Shares Outstanding | 363.40M |
| Shares Change (YoY) | +38.44% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 24.11% |
| Float | 183.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.82 |
| Forward PS | 25.80 |
| PB Ratio | 3.09 |
| P/TBV Ratio | 4.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.47.
| Current Ratio | 4.16 |
| Quick Ratio | 4.05 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.44 |
Financial Efficiency
Return on equity (ROE) is -65.30% and return on invested capital (ROIC) is -24.71%.
| Return on Equity (ROE) | -65.30% |
| Return on Assets (ROA) | -22.14% |
| Return on Invested Capital (ROIC) | -24.71% |
| Return on Capital Employed (ROCE) | -55.61% |
| Revenue Per Employee | $567,301 |
| Profits Per Employee | -$1.17M |
| Employee Count | 103 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 222.53 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.82% in the last 52 weeks. The beta is 1.27, so LXRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -32.82% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 0.78 |
| Relative Strength Index (RSI) | 48.31 |
| Average Volume (20 Days) | 1,640,973 |
Short Selling Information
The latest short interest is 28.84 million, so 7.94% of the outstanding shares have been sold short.
| Short Interest | 28.84M |
| Short Previous Month | 27.91M |
| Short % of Shares Out | 7.94% |
| Short % of Float | 15.68% |
| Short Ratio (days to cover) | 13.09 |
Income Statement
In the last 12 months, LXRX had revenue of $58.43 million and -$120.62 million in losses. Loss per share was -$0.33.
| Revenue | 58.43M |
| Gross Profit | -25.35M |
| Operating Income | -106.07M |
| Pretax Income | n/a |
| Net Income | -120.62M |
| EBITDA | -105.47M |
| EBIT | -106.07M |
| Loss Per Share | -$0.33 |
Full Income StatementBalance Sheet
The company has $139.01 million in cash and $61.42 million in debt, giving a net cash position of $77.59 million or $0.21 per share.
| Cash & Cash Equivalents | 139.01M |
| Total Debt | 61.42M |
| Net Cash | 77.59M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | 129.44M |
| Book Value Per Share | 0.36 |
| Working Capital | 110.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$101.90 million and capital expenditures -$781,000, giving a free cash flow of -$102.68 million.
| Operating Cash Flow | -101.90M |
| Capital Expenditures | -781,000 |
| Free Cash Flow | -102.68M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
Gross margin is -43.39%, with operating and profit margins of -181.53% and -206.43%.
| Gross Margin | -43.39% |
| Operating Margin | -181.53% |
| Pretax Margin | -206.43% |
| Profit Margin | -206.43% |
| EBITDA Margin | -180.50% |
| EBIT Margin | -181.53% |
| FCF Margin | n/a |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.44% |
| Shareholder Yield | -38.44% |
| Earnings Yield | -31.17% |
| FCF Yield | -26.53% |
Analyst Forecast
The average price target for LXRX is $3.23, which is 196.33% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.23 |
| Price Target Difference | 196.33% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 41.57% |
| EPS Growth Forecast (5Y) | -29.10% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
LXRX has an Altman Z-Score of -10.62 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.62 |
| Piotroski F-Score | 4 |
